TerSera Therapeutics’ Post

Exploring Tamoxifen 20mg: Uses, Dosage, and Considerations Introduction: Tamoxifen 20mg is a medication commonly prescribed in the treatment and prevention of certain types of breast cancer. This guide provides comprehensive information about Tamoxifen 20mg, including its uses, recommended dosage, and important considerations. #tamoxifen20mg #20mgtamoxifen #tamoxifen20 #breastcancer visit now- https://lnkd.in/dDzXDaj2

Great study on the complementary therapies and their perceived impact on recovery and prevention of recurrence in breast cancer survivors. #BreastCancerAwareness #Pinktober #BreastCancer #CancerCare #BreastCancerEducation https://loom.ly/QaZtfH4

Some very good news from Gilead Sciences, as Health Canada authorizes TRODELVY for pre-treated patients with HR+/HER2- metastatic breast cancer. HR+/HER2- metastatic breast cancer patients have limited treatment options, and the market authorization of TRODELVY is a step in the right direction in providing an additional therapy for Canadian patients. Dr. Karen A. Gelmon, a Professor of Medicine at the University of British Columbia and a Medical Oncologist at BC Cancer shares, "Nearly all patients with HR+/HER2- advanced breast cancer will eventually develop resistance to endocrine-based therapies and once they have progressed, their primary treatment option is single-agent chemotherapy. At this point, it is common for persons to receive multiple lines of chemotherapy regimens, with decreasing responses with each new treatment. TRODELVY in this indication with its efficacy is welcome news to patients and to the oncology community." TRODELVY has improved survival in pre-treated HR+/HER2- metastatic breast cancer, to know more, please visit https://lnkd.in/gdw_pcHi

Invasive breast cancer: doing better now than before. And things are looking more optimistic in the last few years with newer options… Early invasive breast cancer during the 1990s, the risk of death within 5 years of diagnosis was just over 14% on average. For women diagnosed during the 2010s, it was nearly 5% on average. And that "although deaths from breast cancer will continue to occur beyond this [5-year mark], the risk during each subsequent five-year period is likely to be lower than during the first five years." https://lnkd.in/ex4YfNb8

🔍 Knowledge is Power! 🔍 Breast cancer isn't just a women's issue; men can be affected too. Did you know that male breast cancer, though rare, accounts for 1% of all breast cancers annually, with a lifetime risk of 1 in 1,000? Understanding the different types of breast cancer can make a huge difference in early detection and treatment. Learn more about male breast cancer and spread the awareness! 📖 Read more: https://lnkd.in/e6kRcwhr #BreastCancerAwareness #MaleBreastCancer #KnowledgeIsPower

In the face of a breast cancer diagnosis, the journey might seem arduous, but within the realm of clinical trials lies a pathway to hope. 🌟 Black women, especially, play a pivotal role in advancing research and treatments. By participating, you're not just fighting for yourself but for countless others. Together, we can rewrite the story of breast cancer. 🌸👩🔬 #BreastCancerResearch #ClinicalTrials #HopeInUnity #BlackWomenInMedicine #RollingOut #BusinessExchange #iamrollingout https://lnkd.in/gMBjZtvT

T-DXd is rapidly expanding in indications, from HER2+, to HER2-low, and most recently to HER2-ultralow breast cancer. At present, most patients with metastatic breast cancer can be considered eligible for the drug. This calls for a concomitant expansion in our efforts to mitigate its side effects: particularly ILD, which can prove life threatening. The 5 S rules help memorizing a simple framework to manage ILD: Screen patients for lung comorbidities, Scan frequently (CT chest every 6-12 weeks), be Synergistic with all the multidisciplinary care team, Suspend T-DXd if ILD is suspected, use Steroids early. Link: https://lnkd.in/dN-mvgTt https://lnkd.in/d7a_sf49

Our latest UKCTOCS paper online this week!

Triple Negative Breast Cancer and Brain Metastases The treatment of metastatic breast cancer (MBC) has improved over the past decade, however prognosis continues to be mitigated by the fact that about 1 in 5 patients with MBC will develop brain metastases (BrM) during their metastatic disease course. 1 This number is even higher for patients with triple-negative breast cancer (TNBC), with studies showing as high as 40% of patients developing BrM. 2, 3 Studies have shown that TNBC portends a worse survival after a diagnosis of BrM compared with non-TNBC subtypes. 4 Given the unique location and biologic properties of BrM, treatment options have historically been limited. Challenges to the treatment of TNBC BrM include a lack of targeted therapies and difficulties in delivery of drug to the brain past the blood-brain barrier (BBB). Herein, we will review the advances in local and systemic therapies to most effectively treat patients with TNBC BrM, including therapies on the horizon currently in clinical trials. https://lnkd.in/djaXdrQ7

Exciting insights emerge from the OXEL study (NCT03487666) in the realm of triple-negative breast cancer (TNBC) treatment. Combining nivolumab and capecitabine leads to a significant increase in peripheral immunoscore (PIS) among TNBC patients—91% compared to 47% with nivolumab alone and 53% with capecitabine alone (log-rank p = 0.08). Additionally, the presence of circulating tumour DNA (ctDNA) is linked to disease recurrence, with no new safety signals observed in the combination arm. More details in the article: https://ow.ly/omMG50Rxgme